Levi M
Dept. of Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Hamostaseologie. 2009 Jan;29(1):68-70.
Recombinant activated factor VII (rFVIIa) is a pro-haemostatic agent that can be used for patients with haemophilia and inhibiting antibodies towards a coagulation factor. Recombinant factor VIIa is, however, increasingly used for several other indications, including patients who experience serious and life-threatening bleeding. In addition, rFVIIa has been evaluated for the prevention of major blood loss in patients undergoing surgical procedures that are known to be associated with major blood loss. In this manuscript we review the data on efficacy and safety of rFVIIa in the prevention of excessive blood loss and transfusion requirements in the perioperative period. We conclude that recombinant factor VIIa is a promising agent for perioperative prevention of major blood loss but that its efficacy will probably vary between specific clinical settings. Its exact place in surgery warrants further clinical trials in various situations that will also more precisely determine the safety of this intervention.
重组活化凝血因子 VII（rFVIIa）是一种促止血剂，可用于血友病患者以及对凝血因子产生抑制性抗体的患者。然而，重组凝血因子 VIIa 越来越多地用于其他多种适应症，包括经历严重且危及生命出血的患者。此外，rFVIIa 已被评估用于预防已知与大量失血相关的外科手术患者的大出血。在本手稿中，我们回顾了 rFVIIa 在围手术期预防过度失血和输血需求方面的疗效和安全性数据。我们得出结论，重组凝血因子 VIIa 是围手术期预防大出血的一种有前景的药物，但其疗效可能因具体临床情况而异。它在手术中的确切地位需要在各种情况下进行进一步的临床试验，这也将更精确地确定这种干预措施的安全性。
